This week in health care policy: November 13-20

Photo Credit: Getty

Drug innovation and FDA

A leukemia vaccine cuts the risk of death by 41 percent. In a Phase 3 trial, galinpepimut-S, a vaccine developed at Memorial Sloan Kettering, extended median survival by 10 to 24 months for AML patients in second remission who couldn’t get a stem cell transplant. The vaccine trains the immune system to attack a protein found on leukemia cells. It’s a good example of how prescription drug innovation benefits consumers.

FDA approves an all-oral breast cancer combination. Genentech’s Wilserdly (giredestrant) plus everolimus is now approved for certain breast cancer patients. In the trial, it cut the risk of progression or death by 62 percent, nearly doubling median progression-free survival to 10 months.

FDA moves to pull a liquid statin over missing paperwork. The FDA proposed withdrawing approval of FloLipid, Salerno Pharmaceuticals’ oral liquid simvastatin, because the company failed to file required annual reports. FDA raised no safety or efficacy concerns.

Medicare, Medicaid, and the new Congress

Jeffries backs lowering the Medicare age and covering all children. Likely next Speaker Hakeem Jeffries told NBC News he supports lowering the Medicare eligibility age, adding dental, vision, and hearing benefits, and covering “all the kids in the United States of America.” Sen. Bernie Sanders (I-VT), the incoming HELP chair, called it the first year of his four-year Medicare for All transition.

Recently, I projected that, taken together, Democratic proposals for health care reform could cost more than $10 trillion over the next ten years. Affordability was a prominent issue in the recent election. In a study released earlier this week, I described what policies I believe policymakers at the state and national level should be doing to control the costs of health care.

Hospitals renew their push to block the 340B rebate model. The AHA and co-plaintiffs asked a federal court in Maine to stop HRSA’s 340B rebate model before it takes effect January 1, arguing it would impose hundreds of millions of dollars in costs on 340B hospitals. For background on the program, see my comments to The Epoch Times on tightening the 340B loophole.

CMS gives states six more months on work requirements. States can opt into a hold-harmless period through June 30, 2027, during which CMS won’t penalize them for not yet terminating coverage over work requirements. Democrats have indicated that they want to repeal the work requirements when they take over Congress in January.

CMS proposes a sweeping anti-fraud rule. The “CRUSH” proposed rule (CMS-6098-P) covers Medicare, Medicaid, and the ACA marketplaces, with new exclusion and enrollment authorities and Medicare Advantage risk-adjustment audit recoveries extrapolated back to 2018. CMS estimates about $90 billion in savings over 10 years.

Medicare Advantage, ACOs, and taxpayer spending. Part 2 of a Health Affairs Forefront series examines how Medicare Advantage plans and ACOs have actually cost taxpayers without providing the promised benefits.

Public comments pushed up Medicare physician pay. A Health Affairs study found that Medicare increased reimbursement values for about 10 percent of physician services after public comments, demonstrating that even systems that are supposed to be neutral and objective are not immune from special interest lobbying.

AI in health care

Amazon’s AI agents take on scheduling and prescriptions. AWS expanded Amazon Connect Health so patients can book appointments, request refills, and handle other routine tasks in a single after-hours call, with handoffs to staff for urgent or clinical questions.

Health systems move from AI copilots to AI agents. Becker’s examines where health systems are first deploying AI agents that complete tasks on their own rather than just assisting staff.

Doctors have a new assistant. A Wall Street Journal opinion piece looks at how AI is changing physicians’ day-to-day work. My earlier column on the ways AI is already improving lives makes a similar case.

Rules and regulatory actions

CMS reports $110 billion in improper payments. CMS’s FY2026 improper payments report puts improper payments at $46.8 billion in Medicaid, $34.0 billion in traditional Medicare, $23.9 billion in Medicare Advantage, and $5.2 billion in Part D.

FDA drafts guidance on new trial designs. The draft guidance explains how drug and biologic sponsors can use Bayesian methods for primary analyses, interim analyses, and dose selection.

Other health policy work

CRFB’s health solutions summit. CRFB posted a recap of its fifth annual Health Solutions Summit, which included Mark Cuban and panels on Medicare and post-OBBB Medicaid.

Michael Cannon advocates for “Universal Health Accounts.” Cannon published a new Cato policy analysis, Universal Health Accounts: A Politically Feasible Way to Reduce Health-Related Tax Distortions.

Paragon on Medicare’s “pay and don’t chase” problem. Boris Vabson argues that traditional Medicare loses tens of billions of dollars a year because of weak enforcement after claims are paid, and lays out how CMS can fix it.

Paragon on whether the OBBB cut Medicaid. Brian Blase argues that KFF’s description of the OBBB as a Medicaid “cut” contradicts how KFF treated the ACA’s Medicare reductions in 2012. I’ve made a similar argument that Medicaid “cuts” are not cuts.